NASDAQ:TSVT 2seventy bio (TSVT) Stock Price, News & Analysis $5.00 0.00 (0.00%) As of 05/13/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 2seventy bio Stock (NASDAQ:TSVT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 2seventy bio alerts:Sign Up Key Stats Today's Range$5.00▼$5.0050-Day Range$4.89▼$5.0052-Week Range$2.29▼$5.30VolumeN/AAverage Volume630,937 shsMarket Capitalization$266.15 millionP/E RatioN/ADividend YieldN/APrice Target$4.25Consensus RatingReduce Company Overview2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.Read More… 2seventy bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreTSVT MarketRank™: 2seventy bio scored higher than 31% of companies evaluated by MarketBeat, and ranked 786th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.9 / 5Analyst RatingReduce Consensus Rating2seventy bio has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst Coverage2seventy bio has only been the subject of 4 research reports in the past 90 days.Read more about 2seventy bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 2seventy bio are expected to grow in the coming year, from ($1.46) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 2seventy bio is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 2seventy bio is -2.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio2seventy bio has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about 2seventy bio's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted5.37% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 2seventy bio has recently decreased by 31.48%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield2seventy bio does not currently pay a dividend.Dividend Growth2seventy bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.37% of the float of 2seventy bio has been sold short.Short Interest Ratio / Days to Cover2seventy bio has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 2seventy bio has recently decreased by 31.48%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.30 News Sentiment2seventy bio has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for 2seventy bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TSVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added 2seventy bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, 2seventy bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,400,018.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of 2seventy bio is held by insiders.Percentage Held by Institutions93.90% of the stock of 2seventy bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 2seventy bio's insider trading history. Receive TSVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TSVT Stock News HeadlinesWeiss Ratings Reaffirms Sell (D-) Rating for 2seventy bio (NASDAQ:TSVT)May 12, 2025 | americanbankingnews.com2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers SquibbMay 7, 2025 | businesswire.comTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new blockchain development…May 21, 2025 | Crypto 101 Media (Ad)2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTApril 16, 2025 | businesswire.com2seventy Bio reports Q4 EPS (37c) vs ($1.11) last yearMarch 27, 2025 | markets.businessinsider.com2seventy bio Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 25, 2025 | businesswire.com2seventy Bio price target lowered to $5 from $6 at Morgan StanleyMarch 14, 2025 | markets.businessinsider.com2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVTMarch 14, 2025 | businesswire.comSee More Headlines TSVT Stock Analysis - Frequently Asked Questions How have TSVT shares performed this year? 2seventy bio's stock was trading at $2.94 at the beginning of 2025. Since then, TSVT stock has increased by 70.1% and is now trading at $5.00. View the best growth stocks for 2025 here. How were 2seventy bio's earnings last quarter? 2seventy bio, Inc. (NASDAQ:TSVT) issued its quarterly earnings data on Wednesday, May, 7th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.11. The company had revenue of $22.94 million for the quarter, compared to the consensus estimate of $13.96 million. 2seventy bio had a negative trailing twelve-month return on equity of 53.65% and a negative net margin of 207.25%. Who are 2seventy bio's major shareholders? 2seventy bio's top institutional investors include Goldman Sachs Group Inc. (8.80%), Beryl Capital Management LLC (7.98%), Groupe la Francaise (0.90%) and Charles Schwab Investment Management Inc. (0.79%). Insiders that own company stock include Kynam Capital Management, Lp, Casdin Capital, Llc, William D Baird III, Nick Leschly, Victoria Eatwell, Jessica Snow, Philip D Gregory, Nicola Heffron, Marcela V Maus and Global Healthcare Master Kynam. View institutional ownership trends. How do I buy shares of 2seventy bio? Shares of TSVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 2seventy bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that 2seventy bio investors own include Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Home Depot (HD), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings5/07/2025Today5/21/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TSVT CIK1860782 Webwww.2seventybio.com Phone339-499-9300FaxN/AEmployees440Year FoundedN/APrice Target and Rating Average Stock Price Target$4.25 High Stock Price Target$5.00 Low Stock Price Target$2.00 Potential Upside/Downside-15.0%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-217,570,000.00 Net Margins-207.25% Pretax Margin-207.25% Return on Equity-53.65% Return on Assets-23.67% Debt Debt-to-Equity RatioN/A Current Ratio4.95 Quick Ratio4.95 Sales & Book Value Annual Sales$48.37 million Price / Sales5.50 Cash FlowN/A Price / Cash FlowN/A Book Value$5.04 per share Price / Book0.99Miscellaneous Outstanding Shares53,230,000Free Float47,874,000Market Cap$266.15 million OptionableOptionable Beta1.04 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:TSVT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.